Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients

Inclusion Criteria * Adults of ages 18 to 90 years of both sexes * With positive SARS-CoV-2 carriage confirmed by nasopharyngeal PCR * Signed informed consent * 1- Mild symptoms: Minimum respiratory symptoms or asymptomatic plus positive test * 2- Moderate symptoms: Respiratory symptoms such as cough, mild shortness of breath with mild oxygen desaturation(room air SpO2 \<92% and \>88% or \<88% corrected to \>92% with 2lt of oxygen) Exclusion Criteria * Patients with Severe symptoms: Hypoxia (SpO2 \<88% not corrected by 2 lt nc oxygen) plus severe shortness of breath (excluded) * Patient with very low viral load (threshold cycle \[Ct\] \> 25 per PCR). * Known hypersensitivity to one of the constituents, particularly to xylitol or GSE * Under 18 years of age * Women of childbearing age who are pregnant, breastfeeding mothers, and intend to become pregnant during the study period; unwilling/unable to take a pregnancy test. * Unable to provide informed consent or decline to consent or unwillingness to adhere to the Standard of Care protocol. * Patients with severe symptoms -Hypoxia (SpO2 \<88% not corrected by 2 liter non- concentrated oxygen) plus severe shortness of breath * History of immunodeficiency or are currently receiving immunosuppressive therapy. * Have had a planned surgical procedure within the past 12 weeks. * Already part of this trial, recruited at a different hospital. * Patient unable to perform oro-nasopharyngeal decolonization * Patients with acute exacerbation of severe comorbidities like heart disorders Chronic Obstructive Pulmonary Disease (COPD), Heart Failure New York Heart Association (NYHA) Class 3 and 4 and/or diseases with severe oxygenation problems * Patients on Remdesivir and/or other clinical trials.